KMDA Stock News 13.42 05/09/2014 19:39:13 Kamada Ltd (KMDA)
Post# of 273322
Posted On: 05/09/2014 8:39:19 PM
Kamada Ltd (KMDA) 13.42 $KMDA
Kamada Reports First Quarter Financial Results
Business Wire - Thu May 08, 6:40AM CDT
Kamada Ltd. (NASDAQ: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three months ended March 31, 2014.
Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles
M2 - Mon Apr 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6hzdk/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchiectasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Gilead Sciences, Inc. - Grifols, S.A. - Chiesi Farmaceutici SpA - Zambon Company S.p.A. - Bayer AG - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Edmond Pharma Srl - Savara Inc. - Clarassance, Inc. - Alitair Pharmaceuticals, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - ARD-3150 - ciprofloxacin - aztreonam - ARD-3100 - R&D Progress - AZD-5069 - alpha-1-proteinase inhibitor (human) - BAY-858501 - vancomycin - GSK-2793660 - erdosteine - CG-1011 - Neutrophil Elastases Inhibitors - PUR-0400 - dapsone - ALT-07 - sargramostim - PUR-1000 - ZP-044 For more information visit http://www.researchandmarkets.com/research/q6...chiectasis
Kamada Announces Significantly Improved Infusion Rate for Glassia(R)
Business Wire - Thu Apr 24, 7:03AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia(R) (Alpha1-Proteinase Inhibitor -Human); this improvement was recently approved by the U.S. Food and Drug Administration (FDA). Glassia, which is marketed in the U.S. through a strategic partnership by Baxter International Inc., is the first and only ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) approved by the FDA and is indicated as a chronic augmentation and maintenance therapy in adults with alpha-1 antitrypsin deficiency (AATD, or Inherited Emphysema).
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Mon Mar 24, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema).
Outbrain Appoints Ziv Kop As COO
PR Newswire - Fri Mar 21, 12:30PM CDT
Outbrain, the leading content discovery platform, today announced that Ziv Kop, founding member of Outbrain's Board of Directors and former Managing Partner at GlenRock Israel, has joined the company as Chief Operating Officer.
Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May
Business Wire - Fri Mar 21, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it expects to report top-line data from the pivotal Phase 2/3 clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema) by the end of April or the beginning of May. Previously the Company expected to report the data by the end of the first quarter of 2014. Kamada plans to issue a news release in advance of the announcement of top-line data with the specific date and time of the data release.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes
Business Wire - Wed Mar 05, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control. Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels, and eventually, full external insulin dependence.
Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
Business Wire - Tue Mar 04, 7:02AM CST
Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB(R) as a post-exposure prophylaxis (PEP) for rabies.
Kamada Ltd. [KMDA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Mon Feb 24, 9:00AM CST
What:
Kamada to Ring The NASDAQ Stock Market Opening Bell on February 25, 2014
Business Wire - Mon Feb 24, 7:31AM CST
Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening Bell at The NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Tuesday, February 25, 2014.
Kamada to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Thu Feb 20, 11:31AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that David Tsur, Kamada's Co-Founder and Chief Executive Officer, will deliver a corporate overview at the 2014 RBC Capital Markets' Global Healthcare Conference taking place from February 25-26, 2014 at the New York Palace Hotel. Mr. Tsur's presentation will take place on Wednesday, February 26th at 10:30 a.m. Eastern time.
Emphysema - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5thttd/emphysema) has announced the addition of the "Emphysema - Pipeline Review, H2 2013" report to their offering. 'Emphysema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Emphysema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emphysema. Scope - A snapshot of the global therapeutic scenario for Emphysema. - A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Emphysema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Emphysema Overview Therapeutics Development Emphysema - Pipeline Products Glance Clinical Stage Products Early Stage Products Unknown Stage Products Icure Pharmaceutical Inc. Emphysema - Therapeutics Assessment Drug Profiles Alpha 1-Proteinase Inhibitor - Drug Profile HI-164OV - Drug Profile Lysine Acetylsalicylate - Drug Profile Alpha-1 Antitrypsin With rHuPH20 - Drug Profile Drug For Emphysema - Drug Profile Retinoic Acid Receptor Agonists - Drug Profile formoterol fumarate Patch - Drug Profile Featured News & Press Releases Companies Mentioned Protalix BioTherapeutics, Inc. Bioxyne Limited Kamada Ltd. Intrexon Corporation Medestea Research & Production S.p.A. Northern Therapeutics, Inc. Icure Pharmaceutical Inc. For more information visit http://www.researchandmarkets.com/research/5thttd/emphysema About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kamada Reports 2013 Fourth Quarter and Full Year Financial Results
Business Wire - Wed Feb 05, 5:30AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and 12 months ended December 31, 2013.
Kamada to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call on Wednesday, February 5, 2014
Business Wire - Thu Jan 30, 12:10PM CST
Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release its financial results for the fourth quarter and full year ended December 31, 2013 prior to the market open on Wednesday, February 5, 2014.
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/jj5jz9/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013" report to their offering. 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. Scope - A snapshot of the global therapeutic scenario for Alpha- Antitrypsin Deficiency. - A review of the Alpha- Antitrypsin Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alpha- Antitrypsin Deficiency pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sangamo BioSciences, Inc. Grifols, S.A. rEVO Biologics Alnylam Pharmaceuticals, Inc. Protalix BioTherapeutics, Inc. Kamada Ltd. Applied Genetic Technologies Corporation Intrexon Corporation Polyphor Ltd. iBio, Inc. Amunix, Inc. OrphageniX, Inc. Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/jj5jz9/alpha About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Six Israeli Biotech New Issues Set A Blistering Pace
at Investor's Business Daily - Tue Jan 14, 5:12PM CST
Biotech stocks have been gaining in strides lately, with the 279-stock industry group up 15% so far in January and ahead 85% over the past 52 weeks. Most of those are U.S.-based. But 11 stocks in the group are Israeli. That is more biotechs than...
Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Wed Dec 11, 7:45AM CST
Kamada Ltd. (Nasdaq and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces completion of the pivotal Phase II/III clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema). Kamada expects to report top-line results from this study in the first quarter of 2014.
Kamada Announces Appointment of Amir London as Senior Vice President, Business Development
Business Wire - Mon Dec 09, 8:00AM CST
Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the appointment of Amir London to the newly-created position of Senior Vice President, Business Development. Mr. London will serve as a member of Kamada's executive leadership team and will lead Kamada's commercial strategy and business development efforts to advance the market opportunities for the company's protein therapeutics platform through a variety of initiatives including collaborations and partnerships, as well as enhancing Kamada's sales infrastructure.
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kamada Reports First Quarter Financial Results
Business Wire - Thu May 08, 6:40AM CDT
Kamada Ltd. (NASDAQ: KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three months ended March 31, 2014.
Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles
M2 - Mon Apr 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6hzdk/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchiectasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Gilead Sciences, Inc. - Grifols, S.A. - Chiesi Farmaceutici SpA - Zambon Company S.p.A. - Bayer AG - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Edmond Pharma Srl - Savara Inc. - Clarassance, Inc. - Alitair Pharmaceuticals, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - ARD-3150 - ciprofloxacin - aztreonam - ARD-3100 - R&D Progress - AZD-5069 - alpha-1-proteinase inhibitor (human) - BAY-858501 - vancomycin - GSK-2793660 - erdosteine - CG-1011 - Neutrophil Elastases Inhibitors - PUR-0400 - dapsone - ALT-07 - sargramostim - PUR-1000 - ZP-044 For more information visit http://www.researchandmarkets.com/research/q6...chiectasis
Kamada Announces Significantly Improved Infusion Rate for Glassia(R)
Business Wire - Thu Apr 24, 7:03AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia(R) (Alpha1-Proteinase Inhibitor -Human); this improvement was recently approved by the U.S. Food and Drug Administration (FDA). Glassia, which is marketed in the U.S. through a strategic partnership by Baxter International Inc., is the first and only ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) approved by the FDA and is indicated as a chronic augmentation and maintenance therapy in adults with alpha-1 antitrypsin deficiency (AATD, or Inherited Emphysema).
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Mon Mar 24, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema).
Outbrain Appoints Ziv Kop As COO
PR Newswire - Fri Mar 21, 12:30PM CDT
Outbrain, the leading content discovery platform, today announced that Ziv Kop, founding member of Outbrain's Board of Directors and former Managing Partner at GlenRock Israel, has joined the company as Chief Operating Officer.
Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May
Business Wire - Fri Mar 21, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it expects to report top-line data from the pivotal Phase 2/3 clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema) by the end of April or the beginning of May. Previously the Company expected to report the data by the end of the first quarter of 2014. Kamada plans to issue a news release in advance of the announcement of top-line data with the specific date and time of the data release.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Kamada Initiates Phase 2/3 Clinical Trial of Glassia to Treat Newly Diagnosed Pediatric Patients with Type 1 Diabetes
Business Wire - Wed Mar 05, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia(R), the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur on pancreatic beta cells that secrete insulin, thereby compromising insulin level and glycemic control. Over time there is progressive deterioration of self-insulin secretion, poor capability to control glucose levels, and eventually, full external insulin dependence.
Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies
Business Wire - Tue Mar 04, 7:02AM CST
Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB(R) as a post-exposure prophylaxis (PEP) for rabies.
Kamada Ltd. [KMDA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Mon Feb 24, 9:00AM CST
What:
Kamada to Ring The NASDAQ Stock Market Opening Bell on February 25, 2014
Business Wire - Mon Feb 24, 7:31AM CST
Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening Bell at The NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Tuesday, February 25, 2014.
Kamada to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Thu Feb 20, 11:31AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that David Tsur, Kamada's Co-Founder and Chief Executive Officer, will deliver a corporate overview at the 2014 RBC Capital Markets' Global Healthcare Conference taking place from February 25-26, 2014 at the New York Palace Hotel. Mr. Tsur's presentation will take place on Wednesday, February 26th at 10:30 a.m. Eastern time.
Emphysema - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5thttd/emphysema) has announced the addition of the "Emphysema - Pipeline Review, H2 2013" report to their offering. 'Emphysema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Emphysema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emphysema. Scope - A snapshot of the global therapeutic scenario for Emphysema. - A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Emphysema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Emphysema Overview Therapeutics Development Emphysema - Pipeline Products Glance Clinical Stage Products Early Stage Products Unknown Stage Products Icure Pharmaceutical Inc. Emphysema - Therapeutics Assessment Drug Profiles Alpha 1-Proteinase Inhibitor - Drug Profile HI-164OV - Drug Profile Lysine Acetylsalicylate - Drug Profile Alpha-1 Antitrypsin With rHuPH20 - Drug Profile Drug For Emphysema - Drug Profile Retinoic Acid Receptor Agonists - Drug Profile formoterol fumarate Patch - Drug Profile Featured News & Press Releases Companies Mentioned Protalix BioTherapeutics, Inc. Bioxyne Limited Kamada Ltd. Intrexon Corporation Medestea Research & Production S.p.A. Northern Therapeutics, Inc. Icure Pharmaceutical Inc. For more information visit http://www.researchandmarkets.com/research/5thttd/emphysema About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kamada Reports 2013 Fourth Quarter and Full Year Financial Results
Business Wire - Wed Feb 05, 5:30AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and 12 months ended December 31, 2013.
Kamada to Host Fourth Quarter and Full Year 2013 Financial Results Conference Call on Wednesday, February 5, 2014
Business Wire - Thu Jan 30, 12:10PM CST
Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release its financial results for the fourth quarter and full year ended December 31, 2013 prior to the market open on Wednesday, February 5, 2014.
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/jj5jz9/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013" report to their offering. 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. Scope - A snapshot of the global therapeutic scenario for Alpha- Antitrypsin Deficiency. - A review of the Alpha- Antitrypsin Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alpha- Antitrypsin Deficiency pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sangamo BioSciences, Inc. Grifols, S.A. rEVO Biologics Alnylam Pharmaceuticals, Inc. Protalix BioTherapeutics, Inc. Kamada Ltd. Applied Genetic Technologies Corporation Intrexon Corporation Polyphor Ltd. iBio, Inc. Amunix, Inc. OrphageniX, Inc. Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/jj5jz9/alpha About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Six Israeli Biotech New Issues Set A Blistering Pace
at Investor's Business Daily - Tue Jan 14, 5:12PM CST
Biotech stocks have been gaining in strides lately, with the 279-stock industry group up 15% so far in January and ahead 85% over the past 52 weeks. Most of those are U.S.-based. But 11 stocks in the group are Israeli. That is more biotechs than...
Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
Business Wire - Wed Dec 11, 7:45AM CST
Kamada Ltd. (Nasdaq and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces completion of the pivotal Phase II/III clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema). Kamada expects to report top-line results from this study in the first quarter of 2014.
Kamada Announces Appointment of Amir London as Senior Vice President, Business Development
Business Wire - Mon Dec 09, 8:00AM CST
Kamada Ltd. (Nasdaq:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the appointment of Amir London to the newly-created position of Senior Vice President, Business Development. Mr. London will serve as a member of Kamada's executive leadership team and will lead Kamada's commercial strategy and business development efforts to advance the market opportunities for the company's protein therapeutics platform through a variety of initiatives including collaborations and partnerships, as well as enhancing Kamada's sales infrastructure.
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)